Haofan Biosciences: intends to acquire 100% equity of Hangzhou Foster for approximately 160 million yuan.

Haofan Biology announced that the company plans to use 160 million yuan of its own or self-raised funds in two phases. After the completion of the first phase of equity transfer, the company will obtain 85% equity of Hangzhou Foster, and after the completion of the second phase of equity transfer, the company will obtain 100% equity of Hangzhou Foster. Hangzhou Foster is a company specializing in research and development, production, and sales of high-end intermediates, specialty raw materials drugs, and undertakes some CDMO business. This acquisition aims to obtain the existing surplus production capacity of the target company, improve the company's insufficient production capacity, and enhance the supply capacity of the company's products.